Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial
Autore:
Fava, M; Dunner, DL; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J; Cohen, M;
Indirizzi:
Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 Program, Boston, MA 02114 USA Univ Washington, Med Ctr, Seattle, WA 98195 USA Univ Washington Seattle WA USA 98195 gton, Med Ctr, Seattle, WA 98195 USA Healthcare Technol Syst LLC, Madison, WI USA Healthcare Technol Syst LLC Madison WI USA nol Syst LLC, Madison, WI USA Inst Psychiat Res, Wichita, KS USA Inst Psychiat Res Wichita KS USAInst Psychiat Res, Wichita, KS USA Univ Texas, SW Med Sch, Dept Psychiat, Dallas, TX 75230 USA Univ Texas Dallas TX USA 75230 d Sch, Dept Psychiat, Dallas, TX 75230 USA Rush Presbyterian Hosp, Chicago, IL USA Rush Presbyterian Hosp Chicago ILUSA Presbyterian Hosp, Chicago, IL USA Organon Inc, W Orange, NJ USA Organon Inc W Orange NJ USAOrganon Inc, W Orange, NJ USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 6, volume: 62, anno: 2001,
pagine: 413 - 420
SICI:
0160-6689(200106)62:6<413:EASOMI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUESTIONNAIRE; TOLERABILITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Fava, M Massachusetts Gen Hosp, Depress Clin & Res Program, ACC 812,15 Parkman St,Boston, MA 02114 USA Massachusetts Gen Hosp ACC 812,15 Parkman St Boston MA USA 02114 A
Citazione:
M. Fava et al., "Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial", J CLIN PSY, 62(6), 2001, pp. 413-420

Abstract

Objective: To evaluate the efficacy and safety of mirtazapine in depressedoutpatients who have shown nonresponse or intolerance to selective serotonin reuptake inhibitor (SSRI) therapy. Method: In this open-label, 8-week; study, the efficacy and safety of mirtazapine among 103 outpatients with DSM-IV major depressive disorder who had failed previous therapy with an SSRI (fluoxetine, paroxetine, or sertraline) were evaluated. The primary efficacy measure was the 17-item Hamilton Rating Scale for Depression (HAM-D-17), and safety assessments included reported adverse events, routine laboratoryassessments, physical examinations, and assessments of vital signs. A 4-day washout period followed by mirtazapine treatment was compared with an immediate switch from the SSRI to mirtazapine. Results: Based un mean HAM-D-17scores at endpoint and response rates of 48% based on the criterion of greater than or equal to 50% reduction in HAM-D-17 score, mirtazapine was found to be an effective treatment fur a substantial proportion of patients forwhom an SSRI was ineffective and/or poorly tolerated. Mirtazapine was welltolerated, with sedation and appetite increase/weight gain the most commonly reported adverse events. In addition, no difference in efficacy, safety,or tolerability was observed fur patients undergoing an immediate switch from an SSRI (after having been tapered to the minimal effective dose) to mirtazapine, compared with those undergoing the imposition of a 4-day drug-free washout. Conclusion: These results suggest that an immediate switch to mirtazapine may be a valid therapeutic option among patients who cannot tolerate or do not respond to SSRIs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:34:09